Long-term debt · 2021–2025
Ascendis Pharma long-term debt
$453M+19.4% · FY2025
Ascendis Pharma (ASND) reported $453M in long-term debt for fiscal 2025, +19.4% year on year.
Long-term debt — Long-term debt is borrowing due more than a year out. A large figure is normal for capital-intensive businesses and says nothing on its own about financial health.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2021–2025 compound annual growth +42.1%
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
Long-term debt at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascendis Pharma long-term debt |url=https://companiesranked.com/en/company/ascendis-pharma/long-term-debt |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascendis Pharma long-term debt. CompaniesRanked. https://companiesranked.com/en/company/ascendis-pharma/long-term-debtBibTeX
@misc{companiesranked-en-company-ascendis-pharma-long-term-debt-2026,
author = {{CompaniesRanked}},
title = {{Ascendis Pharma long-term debt}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascendis-pharma/long-term-debt}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-046590 · February 11, 2026
{{cite web |title=Ascendis Pharma long-term debt — 20-F (0001193125-26-046590) |url=https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.